Prescribing of pancreatic enzyme therapy for malabsorption in unresectable pancreatic cancer: Cross-sectional survey across New Zealand and Australia.

Landers, A; Brown, H; Russell, K; Fanning, N; Fu, F; McKenzie, C; Agar, MR; Yenson, VM; Clarke, K; Windsor, J

Prescribing of pancreatic enzyme therapy for malabsorption in unresectable pancreatic cancer: Cross-sectional survey across New Zealand and Australia.

Landers, A Brown, H Russell, K Fanning, N Fu, F McKenzie, C Agar, MR Yenson, VM Clarke, K Windsor, J

Permalink

Publisher:: Elsevier
Publication Type:: Journal Article
Citation:: Pancreatology, 2024, pp. S1424-3903(24)00758-0
Issue Date:: 2024-10-13

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Published versionAdobe PDF (572.78 kB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Landers, A
dc.contributor.author	Brown, H
dc.contributor.author	Russell, K
dc.contributor.author	Fanning, N
dc.contributor.author	Fu, F
dc.contributor.author	McKenzie, C
dc.contributor.author	Agar, MR
dc.contributor.author	Yenson, VM
dc.contributor.author	Clarke, K
dc.contributor.author	Windsor, J
dc.date.accessioned	2024-10-27T23:25:27Z
dc.date.available	2024-10-12
dc.date.available	2024-10-27T23:25:27Z
dc.date.issued	2024-10-13
dc.identifier.citation	Pancreatology, 2024, pp. S1424-3903(24)00758-0
dc.identifier.issn	1424-3903
dc.identifier.issn	1424-3911
dc.identifier.uri	http://hdl.handle.net/10453/181584
dc.description.abstract	OBJECTIVE: To investigate the practices of clinicians prescribing pancreatic enzyme replacement therapy (PERT) for unresectable pancreatic cancer in Aotearoa New Zealand and Australia. METHODS: A mixed media advertising campaign was used to recruit appropriate clinicians to complete a questionnaire that collected demographic data, information regarding prescribed medication, and awareness of PERT guidelines. RESULTS: The study recruited 161 clinicians, with 93 and 68 respondents from Aotearoa New Zealand and Australia respectively. Most respondents from both countries were experienced gastrointestinal surgeons and dietitians. Aotearoa New Zealand clinicians and dietitians used faecal elastase more frequently to diagnose PEI than other groups. Clinicians had a tendency to under-prescribe PERT, and to advise incorrectly on the timing of the medication. The majority of clinicians from Aotearoa New Zealand and Australia were not aware of any best practice clinical guidelines for PERT (70 % and 77 %, respectively). CONCLUSION: This study suggests clinicians are over-reliant on faecal elastase to diagnose PEI and are uncertain about the correct dose and timing of PERT for optimal patient benefit in those with unresectable pancreatic cancer. Most clinicians were not aware of best practice guidelines.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	Elsevier
dc.relation.ispartof	Pancreatology
dc.relation.isbasedon	10.1016/j.pan.2024.10.008
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	1103 Clinical Sciences
dc.subject.classification	Gastroenterology & Hepatology
dc.subject.classification	3202 Clinical sciences
dc.title	Prescribing of pancreatic enzyme therapy for malabsorption in unresectable pancreatic cancer: Cross-sectional survey across New Zealand and Australia.
dc.type	Journal Article
utslib.location.activity	Switzerland
utslib.for	1103 Clinical Sciences
pubs.organisational-group	University of Technology Sydney
pubs.organisational-group	University of Technology Sydney/Faculty of Health
pubs.organisational-group	University of Technology Sydney/UTS Groups
pubs.organisational-group	University of Technology Sydney/UTS Groups/Improving Palliative, Aged and Chronic Care through Clinical Research and Translation (IMPACCT)
utslib.copyright.status	open_access	*
dc.rights.license	This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/
dc.date.updated	2024-10-27T23:25:25Z
pubs.publication-status	Published online

Abstract:

OBJECTIVE: To investigate the practices of clinicians prescribing pancreatic enzyme replacement therapy (PERT) for unresectable pancreatic cancer in Aotearoa New Zealand and Australia. METHODS: A mixed media advertising campaign was used to recruit appropriate clinicians to complete a questionnaire that collected demographic data, information regarding prescribed medication, and awareness of PERT guidelines. RESULTS: The study recruited 161 clinicians, with 93 and 68 respondents from Aotearoa New Zealand and Australia respectively. Most respondents from both countries were experienced gastrointestinal surgeons and dietitians. Aotearoa New Zealand clinicians and dietitians used faecal elastase more frequently to diagnose PEI than other groups. Clinicians had a tendency to under-prescribe PERT, and to advise incorrectly on the timing of the medication. The majority of clinicians from Aotearoa New Zealand and Australia were not aware of any best practice clinical guidelines for PERT (70 % and 77 %, respectively). CONCLUSION: This study suggests clinicians are over-reliant on faecal elastase to diagnose PEI and are uncertain about the correct dose and timing of PERT for optimal patient benefit in those with unresectable pancreatic cancer. Most clinicians were not aware of best practice guidelines.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/181584